Literature DB >> 12506777

Genetic and environmental risk factors for idiopathic inflammatory myopathies.

Ann M Reed1, Steven R Ytterberg.   

Abstract

Although the studies discussed are beginning to reveal a number of genetic and possible environmental risk factors for myositis, further investigations are needed to fully understand and classify these syndromes. The difficulties in this process include small numbers of subjects with varying disease phenotypes available for study, polygenic risk factors for which it remains unclear which are primary and which are secondary or linked genes, and the lack of validated environmental exposure assessment tools. New technologies and international collaborative approaches, however, may overcome some of these difficulties and allow us to identify genetic and environmental risk factors, as well as the critical gene-environment interactions in the IIM and its subgroups. Nonetheless, our understanding of these diseases is still in the early stages. Although we have learned a great deal about these disorders through detailed investigations over the last several decades, we have even further to go to understand the environmental triggers and genetic susceptibilities for the myositis syndromes.

Entities:  

Mesh:

Year:  2002        PMID: 12506777     DOI: 10.1016/s0889-857x(02)00029-7

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  11 in total

Review 1.  Dermatomyositis.

Authors:  M S Krathen; D Fiorentino; V P Werth
Journal:  Curr Dir Autoimmun       Date:  2008

2.  Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; Frederick W Miller
Journal:  JAMA       Date:  2011-01-12       Impact factor: 56.272

Review 3.  Risk factors and disease mechanisms in myositis.

Authors:  Frederick W Miller; Janine A Lamb; Jens Schmidt; Kanneboyina Nagaraju
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

4.  The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis.

Authors:  Adam Schiffenbauer; Sara Faghihi-Kashani; Terrence P O'Hanlon; Willy A Flegel; Sharon D Adams; Ira N Targoff; Chester V Oddis; Steven R Ytterberg; Rohit Aggarwal; Lisa Christopher-Stine; Ejaz A Shamim; Paul F Dellaripa; Sonye K Danoff; Andrew L Mammen; Frederick W Miller
Journal:  Semin Arthritis Rheum       Date:  2018-02-14       Impact factor: 5.532

5.  Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians.

Authors:  Gulnara Mamyrova; Terrance P O'Hanlon; Jason B Monroe; Danielle Mercatante Carrick; James D Malley; Sharon Adams; Ann M Reed; Ejaz A Shamim; Laura James-Newton; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2006-12

Review 6.  The heterogeneity of juvenile myositis.

Authors:  Lisa G Rider
Journal:  Autoimmun Rev       Date:  2006-09-05       Impact factor: 9.754

7.  Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies.

Authors:  Terrance P O'Hanlon; Lisa G Rider; Adam Schiffenbauer; Ira N Targoff; Karen Malley; Janardan P Pandey; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2008-10

8.  Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center's experience.

Authors:  Anjali Patwardhan; Robert Rennebohm; Igor Dvorchik; Charles H Spencer
Journal:  Pediatr Rheumatol Online J       Date:  2012-09-20       Impact factor: 3.054

Review 9.  Practical approach to the patient with acute neuromuscular weakness.

Authors:  Rajeev Nayak
Journal:  World J Clin Cases       Date:  2017-07-16       Impact factor: 1.337

Review 10.  Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?

Authors:  Sarah L Tansley; Neil J McHugh; Lucy R Wedderburn
Journal:  Arthritis Res Ther       Date:  2013-04-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.